Sarepta Taps AbbVie Veteran Michael Severino as CEO; Outgoing Chief Ingram to Consult
SRPT sits 57% above its 52-week low of $10.415.
Summary
Sarepta Therapeutics has named Michael Severino, M.D. as CEO, succeeding Doug Ingram. Severino, an AbbVie and Tessera alum, receives a $35M equity grant. Ingram will consult through 2026.
Key Events · Executive and Board Changes · SRPT
-
New CEO Appointed
Michael Severino, M.D., former AbbVie President and Tessera CEO, will take over as CEO on July 28, 2026, succeeding Doug Ingram.
-
CEO Compensation Package
Under his employment agreement, Severino will receive a $1.18M base salary, a 110% target bonus, and a $35M sign-on equity grant split between one-third RSUs and two-thirds premium-priced options.
-
Outgoing CEO Transition
Doug Ingram is retiring as CEO and board member, then serving as a consultant through December 31, 2026, at a rate of $15,000 per month.
-
Strategic Implications
Severino's extensive R&D background at AbbVie and Amgen could signal a heightened emphasis on pipeline development and precision genetic medicine.
Analysis · SRPT · Life Sciences
Effective July 28, 2026, Sarepta Therapeutics will welcome Michael Severino, M.D.—formerly President at AbbVie and CEO of Tessera—as its new chief executive. He takes the reins from Doug Ingram, who will remain on board as a consultant through year-end. With deep R&D leadership experience at AbbVie and Amgen, Severino's arrival hints at a sharper strategic focus on advancing the pipeline. The board's commitment to securing top-tier talent is underscored by his compensation package, which features a $35 million sign-on equity grant. The transition appears orderly, with Ingram providing continuity during the handoff.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRPT was trading at $16.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $10.42 to $25.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.